Page last updated: 2024-10-15

acetoacetic acid and Obesity, Morbid

acetoacetic acid has been researched along with Obesity, Morbid in 1 studies

acetoacetic acid : A 3-oxo monocarboxylic acid that is butyric acid bearing a 3-oxo substituent.

Obesity, Morbid: The condition of weighing two, three, or more times the ideal weight, so called because it is associated with many serious and life-threatening disorders. In the BODY MASS INDEX, morbid obesity is defined as having a BMI greater than 40.0 kg/m2.

Research Excerpts

ExcerptRelevanceReference
"Three clinical studies were conducted: a bariatric surgery cohort study of participants with morbid obesity who underwent either Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) studied over four and twelve weeks, and two randomized placebo-controlled, crossover double blind studies of liraglutide vs."5.69Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity. ( Alexandrou, A; Angelidi, AM; Connelly, MA; Kokkinos, A; Mantzoros, CS; Mingrone, G; Sanoudou, D, 2023)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Angelidi, AM1
Kokkinos, A1
Sanoudou, D1
Connelly, MA1
Alexandrou, A1
Mingrone, G1
Mantzoros, CS1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Comparative Study of the Effects of Roux en Y Gastric Bypass and Sleeve Gastrectomy on Postprandial Gut Hormone Responses, Glycemia and Lipid Profile, Weight Loss, and Indices of Cardiovascular Risk[NCT03851874]28 participants (Actual)Interventional2011-10-31Completed
Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI[NCT01562678]Phase 428 participants (Actual)Interventional2012-03-31Completed
Saxenda: Underlying Mechanisms and Clinical Outcomes[NCT02944500]Phase 428 participants (Actual)Interventional2016-11-30Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change Between Highly Desirable vs. Less Desirable Food Cues in the Effect Size of Cortical Activation During Food Visualization

Effect size (region of interest z-scores, derived from z-maps of the brain) shown below is the difference in parietal cortex activation to highly desirable (high fat or high calorie, e.g. cakes, pies, fries) versus less desirable (low fat or low calorie, e.g. vegetables, fruits) food cues for each treatment condition (liraglutide or placebo) at the end of the treatment period. (NCT01562678)
Timeframe: 18 days of Liraglutide or placebo treatment

Interventionz-scores of activation in cortex (Mean)
Liraglutide-0.42
Placebo0.53

Trials

1 trial available for acetoacetic acid and Obesity, Morbid

ArticleYear
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
    Metabolism: clinical and experimental, 2023, Volume: 138

    Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto

2023
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
    Metabolism: clinical and experimental, 2023, Volume: 138

    Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto

2023
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
    Metabolism: clinical and experimental, 2023, Volume: 138

    Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto

2023
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
    Metabolism: clinical and experimental, 2023, Volume: 138

    Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto

2023
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
    Metabolism: clinical and experimental, 2023, Volume: 138

    Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto

2023
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
    Metabolism: clinical and experimental, 2023, Volume: 138

    Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto

2023
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
    Metabolism: clinical and experimental, 2023, Volume: 138

    Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto

2023
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
    Metabolism: clinical and experimental, 2023, Volume: 138

    Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto

2023
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
    Metabolism: clinical and experimental, 2023, Volume: 138

    Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto

2023